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Integrative annotation and
knowledge discovery of kinase
post-translational modifications
and cancer-associated mutations
through federated protein
ontologies and resources
Liang-Chin Huang1, Karen E. Ross2, Timothy R. Baffi3, Harold Drabkin4, Krzysztof J. Kochut5,
Zheng Ruan 1, Peter D’Eustachio 6, Daniel McSkimming7, Cecilia Arighi8, Chuming Chen8,
Darren A. Natale2, Cynthia Smith 4, Pascale Gaudet9, Alexandra C. Newton3, Cathy Wu2,8 &
Natarajan Kannan1
Many bioinformatics resources with unique perspectives on the protein landscape are currently
available. However, generating new knowledge from these resources requires interoperable workflows
that support cross-resource queries. In this study, we employ federated queries linking information
from the Protein Kinase Ontology, iPTMnet, Protein Ontology, neXtProt, and the Mouse Genome
Informatics to identify key knowledge gaps in the functional coverage of the human kinome and
prioritize understudied kinases, cancer variants and post-translational modifications (PTMs) for
functional studies. We identify 32 functional domains enriched in cancer variants and PTMs and
generate mechanistic hypotheses on overlapping variant and PTM sites by aggregating information
at the residue, protein, pathway and species level from these resources. We experimentally test the
hypothesis that S768 phosphorylation in the C-helix of EGFR is inhibitory by showing that oncogenic
variants altering S768 phosphorylation increase basal EGFR activity. In contrast, oncogenic variants
altering conserved phosphorylation sites in the ‘hydrophobic motif’ of PKCβII (S660F and S660C) are
loss-of-function in that they reduce kinase activity and enhance membrane translocation. Our studies
provide a framework for integrative, consistent, and reproducible annotation of the cancer kinomes.
Phosphorylation of serine, threonine and tyrosine residues by protein kinases is a major post-translational modification (PTM) that controls diverse regulatory and signalling mechanisms in cells. Aberrant phosphorylation
is emerging as a common pathologic mechanism, and protein kinases are significantly overrepresented among
mutant proteins in cancers1. It is even thought that in most tumours, at least one protein kinase or phosphatase
gene is affected by mutation, copy number variation, or genetic rearrangements2. There is high interest in protein
1

Institute of Bioinformatics, University of Georgia, Athens, GA, 30602, USA. 2Protein Information Resource (PIR),
Department of Biochemistry and Molecular & Cellular Biology, Georgetown University Medical Center, Washington,
DC, 20007, USA. 3Department of Pharmacology, University of California, San Diego, La Jolla, CA, 92093, USA.
4
The Jackson Laboratory, Bar Harbor, ME, 04609, USA. 5Department of Computer Science, University of Georgia,
Athens, GA, 30602, USA. 6Department of Biochemistry & Molecular Pharmacology, NYU School of Medicine, New
York, NY, 10016, USA. 7Genome, Environment, and Microbiome (GEM) Center of Excellence, University at Buffalo,
Buffalo, NY, 14203, USA. 8Center for Bioinformatics and Computational Biology, University of Delaware, Newark,
DE, 19711, USA. 9SIB Swiss Institute of Bioinformatics, Lausanne, 1015, Switzerland. Liang-Chin Huang and Karen
E. Ross contributed equally to this work. Correspondence and requests for materials should be addressed to N.K.
(email: nkannan@uga.edu)
SCIentIfIC REPOrTS | (2018) 8:6518 | DOI:10.1038/s41598-018-24457-1

1

www.nature.com/scientificreports/
kinases as drug targets, and a growing number of protein kinase inhibitors are gaining FDA approval for therapeutic use, especially in cancer3. For example, mutations in the EGFR protein kinase domain are found in 10–30%
of lung adenocarcinomas, and treatment with tyrosine kinase inhibitors that specifically target the mutant protein
kinase can produce temporary remissions in lung cancer patients4.
Protein kinase activity is often itself controlled by PTMs, with phosphorylation of activation loop residues
increasing the activity of most protein kinases5. The classic example of this mechanism is receptor tyrosine kinase
(RTK) signalling, in which a ligand binding to its target receptor leads to dimerization, trans-autophosphorylation,
and full kinase activation6. Thus, mutations that disrupt PTM of protein kinases could be potentially oncogenic.
Advances in next-generation sequencing and mass spectrometry proteomics technologies have led to an
explosion of data on PTM sites and disease-associated genetic variations. Detection of sites and variants has far
outpaced functional characterization and annotation of the corresponding data. Thus, for the vast majority of
PTM sites and cancer-associated mutations, there is no annotation indicating how or even whether protein function is affected. In addition, many protein kinases are poorly studied, further hindering the annotation of PTMs
and disease variants.
In order to gain insight into the role of PTMs in cancer, it is increasingly necessary to bring together data
from diverse sources. There are numerous gene/protein bioinformatics resources that curate a variety of
non-overlapping information, including PTMs and disease mutations. In addition to the comprehensive protein
resource, UniProt7, there are resources that specialize in specific species such as neXtProt8 for human and the
Mouse Genome Informatics9 (MGI) for mouse. The Protein Ontology10 (PRO) and iPTMnet11 capture specific
data types on proteoforms and post-translational modifications (PTMs), respectively, across multiple species. The
Catalog of Somatic Mutations in Cancer12 (COSMIC) captures information on human cancer-associated variants
and the Protein Kinase Ontology13 (ProKinO) captures information on the sequence, structure and functional
aspects of protein kinase across species. Integrating information from these resources, each of which has its own
unique focus, has the greatest potential for new discovery. In particular, integrating detailed structural and functional knowledge from domain-specific resources with curated information captured in large protein ontologies
and data stores has the potential to provide high-resolution annotation of mutations and PTMs. Several resources
(for example UniProtKB, PRO, neXtProt, and ProKinO) provide Resource Description Framework (RDF) triple
store representations, which makes their content accessible for querying via “SPARQL Protocol and RDF Query
Language” (SPARQL) endpoints, thereby facilitating data integration.
To generate an overall picture of our knowledge of protein kinases, we developed an annotation score that
reflects the aggregated information available about each protein kinase from several protein bioinformatics resources. By comparing this score with a National Institutes of Health (NIH) metric based on protein
kinase mentions in scientific articles and grant applications14, we identified protein kinases that are potentially
under-curated (low annotation scores relative to literature/grant mentions) and protein kinases that are surprisingly richly annotated given relatively modest literature/grant mentions. Next, we identified 32 domains,
including 19 protein kinase domains, in 27 protein kinases that are statistically enriched in both cancer-associated
mutations and PTM sites. Within the enriched domains, there were 103 sites that are both post-translationally
modified and mutated in cancer samples (“mutation-PTM overlapping sites”). To test the idea that PTMs in these
domains are important for regulating kinase activity, we performed two case studies: one focusing on the protein
kinase domain of EGFR, a highly studied and richly annotated protein kinase that has frequent gain-of-function
mutations in cancer and the other focusing on the C-terminal domains of two members of the PKC family,
PRKCB (PKCβ) and PRKCQ (PKCθ), which have loss-of-function mutations in cancer. For the EGFR study, we
performed experiments and structural modelling to test the hypothesis that S768 phosphorylation is inhibitory
and that oncogenic mutations at this position, especially S768I, increase catalytic activity. For the PKC study, we
performed experiments to test the hypothesis that cancer-associated PKC hydrophobic motif (HF-motif) mutations are, in contrast, inhibitory to kinase function. This work demonstrates the power of aggregated federated
queries to provide annotation at multiple levels of granularity that enables hypothesis generation that is not possible using individual data sources.

Results

Coverage of the kinome in protein bioinformatics resources. Although protein kinases have been
extensively studied for their role in human disease, much of our current understanding of kinase functions is
skewed towards a subset of well-studied protein kinases. Assessing our level of knowledge about protein kinases is
important because it allows us to identify knowledge gaps and to define future priorities for experimental and bioinformatics work. The National Institutes of Health (NIH) recently classified 134 protein kinases as “under-studied” or “dark kinases” using a metric based on the number of publications and the presence/absence of R01
funding: Jensen PubMed score15 <50, no R01s, and PubTator score16 <150. As a complement to the NIH literature-based score, we developed an annotation scoring metric, ω, based on the amount of information available
in curated resources. We gathered information for all the human protein kinases from ProKinO, PRO, neXtProt,
and iPTMnet and their mouse orthologs from MGI (Fig. 1) using a high-level SPARQL federated query (see
Methods and Supplementary Fig. S1a) for all resources except iPTMnet, which does not currently have an RDF
representation and calculated the score as described in Methods. A heatmap of the results shows that ω ranged
from 7.82 for the best-annotated protein kinase, EGFR, to 0.22 for the least well-annotated protein kinase, PSKH2
(Supplementary Data S1). Nearly 200 protein kinases (~35% of the human kinome) had scores of less than 1,
which we define as low-annotated protein kinases.
Next, we compared our annotation score ω to the NIH metric (Fig. 2 and Supplementary Data S1).
Comparisons between ω and the three measurements used in NIH metric, Jensen PubMed score, R01 count,
and PubTator score, are presented in Fig. 2a to c, respectively. Although the figures show high Spearman correlations between ω and the three measurements (Spearman’s rank correlation coefficient ρ = 0.708, ρ = 0.701, and
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Figure 1. A framework for aggregate queries and integrative annotation. Integrative annotation across five
resources, including ProKinO, PRO, iPTMnet, neXtProt, and MGI, is built using SPARQL federated query
against four SPARQL endpoints; iPTMnet data is available via querying through PRO. Types of information are
shown in each RDF data resource. PTM: post-translational modification; PPI: protein-protein interaction; GO:
Gene Ontology.

ρ = 0.757, respectively), the literature-based scores do not entirely reflect the degree to which protein kinases
are annotated in bioinformatics resources. Based on the criteria for the three measurements defined by the NIH
metric, we found that 316 protein kinases (59% of the human kinome) were considered better-studied (BS) by the
NIH metric and had ω greater than 1 (BS/High). These protein kinases are those that are being actively studied
experimentally and are richly annotated in bioinformatics resources. On the other hand, there were 80 protein
kinases (15% of the human kinome) that were considered under-studied (US) by the NIH metric and had ω less
than 1 (US/Low). These are protein kinases that need additional experimental characterization with the subsequent curation of the results. US/Low protein kinases are mainly distributed among Ser/Thr protein kinase families (Fig. 2d, blue nodes), including the CAMK, CMCG, and ACG groups (19%, 17.5%, and 15% of the US/Low
category, respectively); US/Low protein kinases are less common in the tyrosine kinase (TK), tyrosine kinase-like
(TKL), and STE groups (all are 2.5% of the US/Low category).
For the remaining protein kinases, the classifications by the NIH metric and our annotation score ω are not
aligned. The two methods are measuring different aspects of protein kinase knowledge–the NIH metric is measuring unstructured knowledge (mentions in the literature) and research interest (mentions in grant applications)
whereas ω is measuring curated information–so these protein kinases are potentially interesting cases. First, there
are 108 protein kinases (20% of the human kinome) that are considered better-studied by the NIH metric but
received ω less than 1 (BS/Low). This suggests that there is information available about these protein kinases that
are not represented in curated resources or that these protein kinases are currently of high interest (i.e., are being
mentioned in grant application), which could lead to newly published data in the near future. In either case, these
protein kinases would be good candidates to prioritize for further curation. Although BS/Low protein kinase
are found across the kinome (Fig. 2d, red nodes), the proportion of CAMK and STE groups in this category is
particularly high (13% and 12% of the BS/Low category, respectively), indicating that special attention should be
paid to these groups.
Finally, there were 34 protein kinases (6% of the human kinome) that were considered under-studied by the
NIH metric but had ω greater than 1 (US/High). There are multiple reasons why US/High protein kinases may be
more annotation-rich than their score by the NIH metric suggests. First, they may be annotated with data from
high-throughput genomic or proteomic experiments. Results of these experiments are often reported only in
supplemental data tables or are submitted directly to bioinformatics resources and would be missed by the NIH
metric, which counts mentions in scientific articles. Also, our annotation score ω includes information from
MGI on the mouse orthologs of the human protein kinases. Results from model organisms can be very useful in
augmenting the annotation of human proteins and may not be reflected in the NIH metric. The US/High protein
SCIentIfIC REPOrTS | (2018) 8:6518 | DOI:10.1038/s41598-018-24457-1

3

www.nature.com/scientificreports/

Figure 2. NIH metric versus annotation score. Scatter plots of annotation score ω versus the three
measurements (in log scale) used in the NIH metric: (a) Jensen score, (b) R01 count, and (c) PubTator score,
respectively. Spearman’s rank correlation coefficient ρ is shown in each scatter plot. (d) Visualization of the
three annotation categories in the human kinome tree. BS/Low: better-studied protein kinases with low ω (red
nodes); US/High: under-studied protein kinases with high ω (green nodes); US/Low: under-studied protein
kinases with low ω (blue nodes); all the unmarked protein kinases are better-studied protein kinases with high
ω, such as EGFR. Node size scales with the ω score. The five proteins with the highest ω in US/High category
are labelled; the five proteins with the lowest ω in BS/Low and US/Low categories, respectively, are also labelled.
The human kinome tree was generated using KinMap43. Illustration is reproduced courtesy of Cell Signaling
Technology, Inc. (http://www.cellsignal.comwww.cellsignal.com).
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Gene Symbol

UniProtKB ID

Domain

VEA Adj-PV

MEA Adj-PV

Average Score

EGFR

P00533

Pkinase_Tyr

<1.00E-14

<1.00E-14

14.000

ERBB2

P04626

Pkinase_Tyr

4.32E-14

6.70E-06

9.269

BRAF

P15056

Pkinase_Tyr

<1.00E-14

3.42E-05

9.233

MAP2K3

P46734

Pkinase

<1.00E-14

5.33E-05

9.137

PRKCB

P05771

Pkinase

<1.00E-14

3.68E-04

8.717

CHEK2

O96017

Pkinase

<1.00E-14

6.68E-04

8.588

EPHA5

P54756

Pkinase_Tyr

7.55E-14

2.22E-03

7.888

FLT3

P36888

Pkinase_Tyr

1.84E-12

6.90E-04

7.448

EPHA7

Q15375

Pkinase_Tyr

1.53E-11

1.33E-04

7.345

ZAP70

P43403

Pkinase_Tyr

1.20E-03

4.61E-12

7.129

PRKACA

P17612

Pkinase

2.93E-09

8.13E-06

6.811

KIT

P10721

Pkinase_Tyr

6.81E-10

4.21E-04

6.271

LCK

P06239

Pkinase_Tyr

4.20E-03

3.39E-10

5.923

MAP2K1

Q02750

Pkinase

1.45E-04

1.26E-08

5.870

RET

P07949

Pkinase_Tyr

7.21E-04

1.82E-05

3.941

AXL

P30530

Pkinase_Tyr

6.76E-04

7.84E-05

3.638

CSNK1A1L

Q8N752

Pkinase

1.03E-04

2.01E-03

3.341

HCK

P08631

Pkinase_Tyr

5.29E-05

4.97E-03

3.290

FGFR2

P21802

Pkinase_Tyr

5.20E-04

3.47E-03

2.872

AKT1

P31749

PH

<1.00E-14

2.12E-04

8.837

EGFR

P00533

GF_recep_IV

<1.00E-14

1.68E-03

8.387

PAK2

Q13177

PBD

2.15E-11

1.31E-03

6.775

PRKCB

P05771

Pkinase_C

3.68E-08

6.94E-05

5.797

EGFR

P00533

Recep_L_domain

6.07E-07

3.74E-04

4.822

EPHB2

P29323

EphA2_TM

4.08E-03

6.38E-07

4.293

EPHA3

P29320

EphA2_TM

5.75E-06

9.32E-04

4.136

TTN

Q8WZ42

PPAK

1.93E-04

4.29E-05

4.041

EPHB1

P54762

EphA2_TM

3.75E-04

1.60E-04

3.612

BRDT

Q58F21

Bromodomain

3.72E-04

1.66E-03

3.104

TTN

Q8WZ42

fn3

7.85E-04

9.89E-04

3.055

EPHA7

Q15375

EphA2_TM

2.05E-03

5.65E-04

2.968

PRKCQ

Q04759

Pkinase_C

3.83E-03

1.08E-03

2.691

Table 1. Domains enriched in both disease variants and PTMs. Adj-PV: adjusted p-value; Average score: an
average of VEA score and MEA score; bold text: protein kinase domains (either Pkinase or Pkinase_Tyr).
kinases with highest ω belong to the ACG (PRKCQ and PRKACB), STE (STK3), and other (SCYL1 and NEK6)
kinase groups (Fig. 2d, green nodes). Overall, US/High protein kinases are mainly in the CMGC group (23.5% of
the US/High category); on the other hand, there are no US/High protein kinases in the TK group.

Prioritization of overlapping PTMs and disease variants for annotation.

There are 217,925
non-redundant protein kinase missense mutations across all cancer samples in COSMIC v81 (92,222 missense
mutations in genome-wide screened samples) and 16,545 non-redundant PTMs (from iPTMnet) identified in the
human kinome. Many of these mutations and PTMs map to critical functional domains such as the protein kinase
domain as well as to regulatory domains. To prioritize key mutations and PTMs for functional studies and mechanistic annotation, we performed Variant Enrichment Analysis (VEA) and Modification Enrichment Analysis
(MEA) (see Methods). VEA identifies functional domains with the higher-than-expected frequency of mutations
across different cancer samples, while MEA identifies functional domains with the higher-than-expected number
of known modified sites. We identified 32 domains in 27 protein kinases (Table 1) that are significantly enriched
in both cancer-associated variants and PTMs. Protein kinase domains (19/32 enriched domains) were the most
prevalent. Regulatory domains, including the C-terminal domains (Pkinase_C) of PRKCB (PKCβ) and PRKCQ
(PKCθ), the Pleckstrin homology (PH) domain of AKT1, the P21-Rho-binding domain (PBD) of PAK2 and the
transmembrane domain of EphA2 kinase (EphA2_TM), were also identified. Within the enriched domains, there
are 103 positions that are both post-translationally modified and mutated in cancer samples (“mutation-PTM
overlapping sites”; Supplementary Table S1).
Most of the protein kinases with enriched domains (24/27) are better-studied and well-annotated (BS/High;
Fig. 3a). However, the set includes one US/High protein kinase, PKCθ, which we analyse in detail below, and
two BS/Low protein kinases, EPHB1 and CSNK1A1L. Given its association with cancer and the indication that
there is a gap between available data and curated knowledge, further curation of EPHB1 and CSNK1A1L may be
especially valuable.
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Figure 3. Annotation scores of protein kinases with enriched domains and visualization of the enriched domains
in the human kinome tree. (a) Data volume, variety, and annotation score ω for each protein kinase with enriched
VEA and MEA. The name of the protein kinase is shown in the first column in red if it is better-studied or green
if under-studied; gradient colour (red for the maximum and blue for the minimum in the whole human kinome)
indicates the data volume for each variable (column 2–16) and ω (last column). A threshold of high ω ( >1.00) is
shown by a red line. (b) Protein kinases with functional domains with adjusted p-values in VEA or MEA less than
0.005 are represented by red and blue nodes, respectively; node size represents the score in VEA or MEA. Protein
names are labelled only if any of their functional domains shows significant adjusted p-values in both VEA and
MEA; black labels represent proteins with enriched protein kinase domains (either Pkinase or Pkinase_Tyr),
while gray labels show proteins that only have other enriched domains; enriched domains are shown in
parentheses. The human kinome tree was generated using KinMap43. Illustration is reproduced courtesy of Cell
Signaling Technology, Inc. (http://www.cellsignal.comwww.cellsignal.com).
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Figure 4. Variants and PTMs in the six most-enriched protein kinase domains. X-axis: sequence position
and corresponding PKA position/subdomain/motif; y-axis: mutation frequency (logarithmic scale) across all
cancer samples in COSMIC (exact frequency is labelled if it is greater than 100); red dot: phosphorylation; green
dot: ubiquitination; purple dot: acetylation; dot on top of the bar: mutation-PTM overlapping site; Sub I~XI:
subdomain I to XI; β1~5: beta 1 to beta 5 strands; C~I: C-helix to I-helix; GLY: glycine-rich loop; αC: alphaCbeta4 loop; Link: linker; CAT: catalytic loop; Activation: activation loop.

Classification of PTM and variant enriched kinases and domains.

We mapped the 27 protein
kinases with enriched domains onto the human kinome tree (Fig. 3b). The majority (12/19) of the enriched
protein kinase domains fall within the tyrosine kinase group. Enriched regulatory domains are also observed
in tyrosine kinases (e.g., growth factor receptor domain IV (GF_recep_IV) in EGFR). Tyrosine kinases can be
classified as receptor tyrosine kinases (RTKs) or cytoplasmic tyrosine kinases (CTKs) depending on whether
they contain membrane-spanning domains. Among the enriched domains in the tyrosine kinase group, 12 are
found in 9 distinct RTKs, while none are from CTKs (Supplementary Data S1). The reason for this may be that
many of the well-characterized RTK signalling circuits involve autophosphorylation of the RTK as opposed to
trans-phosphorylation of a distinct substrate17; thus, loss of PTM sites in RTKs is more likely to disrupt signalling.
There are several members of the STE group enriched in disease variants, but only three members, MAP2K1,
MAP2K3, and PAK2, have functional domains enriched in PTMs as well. Conversely, the CMGC group has several members with domains enriched in PTMs, but not in cancer variants.
The mutation frequencies (across all the cancer samples in COSMIC) of all positions within the six
most-enriched protein kinase domains are shown in Fig. 4. The glycine-rich loop (Fig. 4, blue highlighting) and
the activation loop (Fig. 4, red highlighting) are hotspots for residues that are mutated and/or post-translationally
modified. There are mutation-PTM overlapping sites within the glycine-rich loop of EGFR, BRAF, and PKCβ
(phosphorylation sites S720, S465/S467, and S352, respectively) and within the activation loops of EGFR, BRAF,
MAP2K3, PKCβ, and CHEK2 (ubiquitination sites K860/K875 of EGFR and K601 of BRAF; phosphorylation
sites T599/S602/S602 of BRAF, T222/Y230 of MAP2K3, T498 of PKCβ, and Y390 of CHEK2). Because the
glycine-rich loop is important for ATP binding and catalytic activity and the activation loop is important for
kinase regulation, mutations in these PTM positions are expected to have a functional impact.
SCIentIfIC REPOrTS | (2018) 8:6518 | DOI:10.1038/s41598-018-24457-1
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Gene

Position

Annotation

Variable
Cellular Component
Reaction
Complex
Pathway

Gene level

Molecular Function

Biological Process

Phenotype
EGFR

PKA Position
Residue level
(General)

Motif
Mutation Count
Mutant Type (MT)

S768

Residue level
(Mutation)

Residue level
(PTM)

SNP

Value

Service

Endosome membrane

neXtProt/MGI

Plasma membrane

neXtProt/MGI

basolateral plasma membrane

neXtProt/MGI

EGFR dimerization

ProKinO

EGF:EGFR dimer [plasma membrane]

ProKinO

L1-EGFR trans-heterodimer

PRO

Constitutive PI3K/AKT Signaling in Cancer

ProKinO

protein localization to nucleus

PRO

Protein binding

neXtProt/MGI

Protein phosphatase binding

neXtProt/MGI

Positive regulation of cell proliferation

neXtProt/MGI

epidermal growth factor receptor signaling pathway

neXtProt/MGI

dilated respiratory conducting tubes

MGI

respiratory distress

MGI

abnormal lung interstitium morphology

MGI

abnormal lung development

MGI

98

ProKinO

N-lobe

ProKinO

C_helix

ProKinO

subdomainIII

ProKinO

252

ProKinO

I

ProKinO/neXtProt

G

ProKinO/neXtProt

(MT = ’I’) rs397517108

neXtProt

(MT = ’I’) rs121913465

neXtProt

(MT = ’G’) rs756614898

neXtProt

Mutation Description

(MT = ’I’) higher levels of basal autophosphorylation

neXtProt

Proteoform

PR:000049851; S768-phosphorylated form; inhibitory effect on EGFR
kinase activity

PRO

Modification

Phosphorylation

PRO/iPTMnet

Enzyme

CAMK2A

iPTMnet

Equivalent Mouse Site Q01279 S770: no evidence for modification
Cellular Component

Plasma membrane

neXtProt/MGI

PRKCB binds diacylglycerol and phosphatidylserine

ProKinO

Complex

Activated PKC beta [plasma membrane]

ProKinO

Glioma

neXtProt

Pathways in cancer

neXtProt

VEGFR2 mediated cell proliferation

neXtProt

Positive regulation of B cell receptor signaling pathway

neXtProt/MGI

Positive regulation of I-kappaB kinase/NF-kappaB signaling

neXtProt/MGI

Positive regulation of NF-kappaB transcription factor activity

neXtProt/MGI

Positive regulation of vascular endothelial growth factor receptor
signaling pathway

neXtProt/MGI

Positive regulation of angiogenesis

neXtProt/MGI

AGC-kinase C-terminal

neXtProt

6

ProKinO

F

ProKinO

Gene level

Biological Process

Residue level
(General)
Residue level
(Mutation)
S661
(S660 in PKCβII)

Functional Domain
Mutation Count
Mutant Type (MT)

C

ProKinO/neXtProt

PR:000049877; S654 & S660- phosphorylated isoform-betaII; mouse

PRO

PR:000049878; S660 & S664- phosphorylated isoform-betaII

PRO

PR:000049879; S660 & S673- phosphorylated isoform-betaII; mouse

PRO

Modification

Phosphorylation

PRO/iPTMnet

Enzyme

PRKCB

iPTMnet

Proteoform
Residue level
(PTM)

neXtProt/MGI

Reaction

Pathway

PRKCB
(PKCβ)

Equivalent Mouse Site P68404 Prkcb S660; phosphorylated
T642 & S661
(T641 & S660 in
PKCβII)

Residue level
(PTM)

iPTMnet

Cytoplasm

PRO/iPTMnet

Proteoform

PR:000049855; T500, T641, S660-phosphorylated PRKCB-2; increased
PRO
protein phosphorylation; increased localization to cytoplasm

Modification

Phosphorylation

PRO

Continued
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Gene

Position

Annotation

Variable
Cellular Component

Plasma membrane

MGI

Autophosphorylation of PKC-theta

ProKinO

Complex

Active PKC theta bound to DAG [plasma membrane]

ProKinO

Negative regulation of T cell apoptotic process

neXtProt/MGI

Positive regulation of T cell activation

neXtProt/MGI

Positive regulation of T cell proliferation

neXtProt/MGI

Positive regulation of telomerase activity

neXtProt

Positive regulation of telomere maintenance via telomerase

neXtProt

Biological Process
PRKCQ
(PKCθ)

S695

Residue level
(Mutation)
Residue level
(PTM)

Service
MGI

Reaction
Gene level

Residue level
(General)

Value
Cytoplasm

Functional Domain

AGC-kinase C-terminal

neXtProt

Mutation Count

1

ProKinO

Mutant Type (MT)

F

ProKinO/neXtProt

Proteoform

PR:000049857; S695-phosphorylated form; increased protein serine/
threonine kinase activity

PRO

Modification

Phosphorylation

PRO/iPTMnet

Equivalent Mouse Site Q02111 S695; phosphorylated

iPTMnet

Table 2. Integrative annotation for case studies.
Hanahan and Weinberg have defined ten hallmarks, or critical biological capabilities, of tumour cells18. Using
information from the COSMIC Cancer Gene Census, which has associated cancer-driver proteins with the hallmarks they affect, we investigated the hallmark profile of protein kinases. (Supplementary Fig. S2 and Supplementary
Data S1). There are 36 protein kinases in the Cancer Gene Census; seven of them (EGFR, ERBB2, BRAF, FLT3,
PRKACA, LCK, and FGFR2) had enriched PTM/mutation domains in our study. Of the 36 protein kinases in
the census, 75% are associated with promoting proliferative signalling and 69% are associated with escaping programmed cell death. Notably, all seven enriched protein kinases have these hallmark properties. These two hallmarks, along with the ability to evade growth inhibitory signals comprise the survival hallmark network (defined by
Wang et al.19) and underlie the fundamental ability of a cancer cell to over-proliferate and form a tumour.

Case studies: variants, PTMs, and cancer. The protein kinase domains and mutation-PTM overlapping

sites identified in the enrichment analysis are candidate regions where aberrant PTMs could contribute to cancer
pathogenesis. To gain insight into mechanisms that could mediate the connection between PTM and cancer variants in these regions, we performed SPARQL federated queries of protein resources to obtain rich information at
the protein, domain, variant, and PTM levels (Supplementary Fig. S1b). We then performed two case studies in
which we selected enriched domains and sites and analysed the detailed query results with the goal of explaining
how PTM disruption could result in tumorigenesis. We also performed cell-based studies to test the functional
impact of mutational alterations of PTM sites in the selected protein kinases. Results of the federated queries that
are relevant to the case studies are summarized in Table 2.

Case study 1: Inhibition of EGFR activity via phosphorylation of S768. We first focused on a
mutation-PTM overlapping site, S768, in the tyrosine kinase domain of EGFR. We chose this example for several
reasons: EGFR was the most enriched protein kinase in our analysis and exemplifies the tyrosine kinase domain,
the most enriched domain in our dataset. EGFR also received the highest annotation score ω (7.81), and S768 was
the most frequently mutated PTM site within the EGFR protein kinase domain (Fig. 4).
EGFR is involved in the epidermal growth factor signalling pathway and positively regulates cell proliferation
in both human and mouse (Table 2, neXtProt/MGI). It is also involved in constitutive PI3K/AKT signalling in
cancer (Table 2, ProKinO). Analysis of copy number variation data from COSMIC (Supplementary Methods)
reveals that EGFR copy number gains significantly outnumber copy number losses in several tumour tissues
(central nervous system, ovary, and pancreas; Supplementary Fig, S3 and Supplementary Data S1), consistent
with an oncogenic, growth-promoting role for EGFR in cancer. There are 252 cancer-associated S768 mutations
at EGFR (Table 2, ProKinO), and two SNPs that result in the substitution of isoleucine for serine at position 768
(rs397517108 and rs121913465, Table 2, neXtProt) are considered pathogenic or likely pathogenic in lung cancer,
according to ClinVar20.
S768 is a phosphosite, and the S768-phosphorylated form of EGFR has reduced kinase activity (PR:000049851;
Table 2, PRO). Mutations at this site change the serine to isoleucine or glycine, both of which would disrupt
phosphorylation (Table 2, ProKinO/neXtProt), and the S768I mutation is associated with higher levels of basal
autophosphorylation (Table 2, neXtProt). Taken together, the PTM and variant annotation support the idea that
S768 phosphorylation is inhibitory to EGFR kinase activity.
To test this hypothesis, we experimentally replaced the serine at position 768 with negatively charged residues
(S768D and S768E), mimicking the constitutively phosphorylated state of EGFR. Consistent with our hypothesis,
cell-based assays show that phosphomimetic mutations S768D and S768E decrease ligand-independent phosphorylation of both the activation loop (Y845) and the C-terminal tail (Y1197) compared to wild-type and oncogenic
(S768I) EGFR (Fig. 5a). Downstream signalling (STAT3 activation) was also negatively affected by the phosphomimetic mutations (Fig. 5a), suggesting that phosphorylation of S768 inhibits EGFR activity.
SCIentIfIC REPOrTS | (2018) 8:6518 | DOI:10.1038/s41598-018-24457-1
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Figure 5. Biochemical impact of S768 phosphorylation in EGFR and S660 mutations in PKCβII. (a) Phosphomimic mutations (S768D, S768E) and oncogenic mutation (S768I) alters the EGFR C-terminal tail (Y1197)
and activation loop (Y845) phosphorylation. EGFR downstream signalling (STAT3) phosphorylation is
also perturbed by the mutations. Each blot is obtained independently using designated antibody from the
same cell lysis samples. An exposure time of 5 min is used for all blots. (b) Structural models comparing
unphosphorylated/phosphorylated (S768) EGFR dimer. The 3D structures are represented by PyMOL44 (c)
Normalized FRET-ratio changes (mean ± SEM) showing an agonist-induced activity of mCherry-tagged
PKCβII wild-type (WT) or PKCβII hydrophobic (HF) motif mutants S660C and S660F in COS-7 cells coexpressing CKAR and treated with UTP (100 μM), followed by PDBu (200 nM). mCherry intensity (inset)
reflects expression levels of overexpressed PKC protein. Data are from three independent experiments. (d)
Representative mCherry images of PKC translocation in COS-7 cells before agonist addition (Basal, t = 0 min),
after UTP addition (UTP, t = 12 min), and after PDBu addition (PDBu, t = 17 min). mCherry vector was used as
a negative control.

S768 is located in the C-helix of subdomain III in the N-lobe of protein kinase domain (Table 2, ProKinO).
Previous studies on EGFR have demonstrated that this region is part of an asymmetric dimer interface critical
for kinase activation21,22. S768 positions the critical juxtamembrane (JM) segment of EGFR through a hydrogen
bonding interaction with N700. Structural modelling suggests that S768 phosphorylation could impair kinase
activity by altering the interactions in the receiver kinase interface and presumably hindering homodimerization
(Fig. 5b). In contrast, the S768I variant cannot be phosphorylated and the hydrophobic nature of isoleucine may
increase dimer stability, leading to the observed constitutive EGFR activity.
The aggregated annotation and our experimental data point to a model where the S768I mutation drives
tumourigenesis by disrupting EGFR autophosphorylation and downstream signalling.
In mouse, Egfr mutations are associated with many respiratory phenotypes (Table 2, MGI), suggesting that
mouse models of Egfr mutations may be relevant to lung diseases. Although the iPTMnet multiple sequence
alignment shows that the position equivalent to S768 in human EGFR is conserved in mouse EGFR (human
EGFR S768 aligns with mouse Egfr S770), there is no experimental phosphorylation information for this mouse
site. It would be interesting to test whether this phosphorylation event and its consequences for EGFR activity are
conserved in mouse.

Case study 2: Role of protein kinase C terminal domain phosphorylation in the regulation
of PKC family kinases. Our second study focused on the protein kinase C (PKC) terminal domain, also

referred to as the C-terminal tail or AGC tail23 (Pkinase_C, Pfam ID: PF00433), which was PTM/mutation
enriched in two members of the PKC family, PRKCB (PKCβ) and PRKCQ (PKCθ). We were interested in this
region/domain because these protein kinases both contain a structurally conserved mutation-PTM overlapping
site. Moreover, PKCθ is the only protein kinase in our enriched dataset that is considered under-studied by the
NIH metric (Jensen PubMed score: 9.4, R01 count: 0, and PubTator score: 96.0). Interestingly, PKCθ was in the
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top 25% of protein kinases according to our annotation score ω (score of 2.4), suggesting that we could use the
aggregated annotation results to gain insight into this protein kinase, despite its status as under-studied. PKCβ
had a similar annotation score (2.0) but is considered better-studied by the NIH metric (Jensen PubMed score:
83.5, R01 count: 126, and PubTator score: 383.8).
The mutation-PTM overlapping site with the greatest number of cancer-associated mutations in the
Pkinase_C domain of PKCβ is S661, which lies in the HF-motif (Fig. 6a). This site corresponds to S660 in PKCβ
isoform 2 (PKCβII; PR:000049855; Table 2, PRO), and S695 in PKCθ (PR:000049857; Table 2, PRO), which is also
a mutation-PTM overlapping site. Moreover, this site is a hotspot of mutation-phosphorylation overlapping sites
across most AGC kinases (Fig. 6b). All the canonical phosphorylatable residues (serine, threonine, and tyrosine)
at this site are phosphorylation targets, and 10 out of these 24 residues (42%) are also mutation sites. Thus, we
performed low-level federated queries for PKCβ and PKCθ to provide functional context for cancer mutations
that alter C-terminal tail phosphorylation.
The HF-motif of PKC isozymes is autophosphorylated shortly after biosynthesis to yield a stable, autoinhibited species that is degradation- and phosphatase-resistant species. When phosphorylated at this key processing
site, both protein kinases are primarily cytosolic and translocate to the membrane following agonist-dependent
generation of diacylglycerol (Table 2, neXtProt/MGI). Kinase-inactive enzymes do not incorporate phosphate at
this site and are shunted for degradation. Thus, mutations that disrupt phosphorylation would be predicted to be
loss-of-function and support a tumour suppressive role of PKC.
Functional analysis of approximately 50 cancer-associated mutations in eight different PKC family members, including PKCβ, indicated that most of the mutations are loss-of-function, reducing or eliminating kinase
activity24; evolutionary analysis performed by KinView25, a sequence visualization tool embedded in ProKinO,
predicted and experimentally validated a PKCβ loss-of-function mutation D523N in the F-helix, although it is not
a mutation-PTM overlapping site (Fig. 4). Correction of a cancer-associated inactivating mutation in PKCβ in a
colon cancer cell line suppressed tumour formation in a xenograft model, supporting a tumour suppressor role
for this isozyme. Consistent with this, higher levels of PKCβII protein in the normal distal epithelia of patients
with colon cancer is associated with better prognosis26. Immunohistological studies annotated in the human
cancer transcriptome27 (www.proteinatlas.org/pathology) reveal that high PKCβII protein expression confers an
increased survival outcome in colon, breast, prostate, lung, and liver cancer, consistent with a tumour suppressor
function. Copy number variation analysis indicates that the copy number for PKCβ and PKCθ varies depending on cancer type (Supplementary Fig. S3). In breast and ovarian cancers, PKCβ copy number amplifications
exceed copy number losses, however, it is unclear how this relates to protein expression. In contrast, in pancreatic
tumours of the carcinoid-endocrine subtype, copy number losses are higher than copy number amplifications.
Similarly, in skin tumours, copy number data suggests PKCθ is a tumour suppressor. The PKCβII S660 mutations
in our dataset were all detected in skin cancers, mainly melanomas. Unfortunately, there are too few PKCβ copy
number variants in melanomas to determine whether there is a significant difference in copy number gains vs.
losses in this cancer subtype.
To assess the effects of the cancer-associated PKC HF-motif mutants on PKC activity, we used the C-Kinase
Activity Reporter28 to measure agonist-evoked PKC kinase activity in live cells (Fig. 5c). mCherry-tagged hPKCβII wild-type or mutant constructs were overexpressed in COS-7 cells co-expressing CKAR and stimulated
with uridine 5’ triphosphate (UTP), a purinergic agonist that elevates the second messengers Ca2+ and diacylglycerol to reversibly activate PKC; they were also treated with PDBu to maximally activate the PKC28. Compared
to wild-type PKCβII, PKCβII S660C and S660F mutants displayed impaired response to both UTP and PDBu
(Fig. 5c). Additionally, the mutants had enhanced plasma membrane translocation indicative of an inability to
autoinhibit and mask the membrane-targeting domains29: whereas membrane translocation of wild-type PKCβII
was observed only following PDBu stimulation, the weaker stimulation by UTP resulted in readily observable
translocation of the mutants (Fig. 5d).
The reduction of activity observed for the HF-motif mutants indicates that they are loss-of-function.
Furthermore, agonist-evoked activity in cells expressing the HF-motif mutants was reduced below endogenous
levels, suggesting that these enzymes possess a dominant-negative function and are suppressing the activity of
endogenous PKC. Additionally, the HF-motif mutants exhibited enhanced membrane translocation upon stimulation with physiological agonist, indicating that they adopt an unprimed, open conformation with exposed
membrane targeting domains29. Thus, the HF-motif is required for the conformational rearrangement that
masks the membrane targeting domains and allows PKC to adopt the catalytically competent, but autoinhibited
conformation.

Discussion

Many biological studies, including proteome-wide analyses and detailed experiments on individual proteins,
benefit from drawing information from multiple resources. Therefore, it is critical to develop methods to facilitate data integration. In this study, we have taken advantage of an RDF representation of information that can be
queried using SPARQL. Specifically, we integrated information of various levels of granularity, including protein/
gene level information from neXtProt and MGI, protein kinase family information from ProKinO, and PTM and
variant-site level information from ProKinO, PRO, and iPTMnet, to explore protein kinase PTMs in the context
of cancer. This approach allowed us to take advantage of the expertise invested in each resource and to conduct a
more detailed analysis than would be possible with any single resource.
Using the aggregated data, we performed two kinome-wide studies: we developed a metric to assess the quantity of annotation available about each protein kinase in curated resources and we identified functional domains
in protein kinases that are statistically enriched in cancer-associated mutations and PTMs. Based on the outcome
of these analyses, we selected two cancer-associated PTMs for in-depth study: S768, located in the protein kinase
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Figure 6. Mutation and PTM sites in the C terminal tail domain of AGC kinases. (a) Mutation and PTM sites
in enriched protein kinase C terminal tail domains. X-axis: sequence position and corresponding PKA position/
subdomain/motif; y-axis: mutation frequency across all cancer samples in COSMIC; red dot: phosphorylation;
yellow dot: methylation; dot on top of the bar: mutation-PTM overlapping site; AST: active-site tether
subdomain; NLT: N-lobe tether subdomain; NFD: NFD motif; T: turn motif; HF: hydrophobic motif. (b)
Mutation and phosphorylation sites in all protein kinase C terminal domains. Sequences of all protein kinase
C terminal tail domains defined by Pfam are aligned to PKA sequence by MAFFT alignment; black rectangles:
subdomains; red rectangles: motifs; residues marked in blue: mutation sites (frequency is ignored); residues
marked in red: phosphorylation sites; residues marked in purple: mutation-phosphorylation overlapping sites.

domain of EGFR, and S661/S695 located in the PKC terminal domains of PKCβ and PKCθ, respectively. Our
annotation score ω revealed 108 protein kinases that are relatively well-studied according to their profile in the literature but are sparsely annotated, suggesting that it would be valuable to prioritize curation efforts for these protein kinases. We also found 34 protein kinases that are considered under-studied in the scientific literature but are
in fact quite richly annotated in bioinformatics resources. One of the protein kinases chosen for in-depth study,
PKCθ, was in this category, and the available annotation was sufficient to propose mechanisms for the oncogenic
effect of PTM site mutations in this protein. Our analysis identified 32 domains in 27 protein kinases that are
statistically enriched in cancer-associated mutations and PTMs. The dual enrichment suggests that disruption
in PTM in these domains may contribute to oncogenesis. This is supported by our in-depth study of EGFR S768.
Review of the integrated data for this site suggested that mutations that lead to loss of phosphorylation at this site
would result in an abnormally active, potentially oncogenic kinase. We performed experiments using phosphomimetic mutations at this position as well as structural modelling to confirm that phosphorylation is likely to reduce
kinase activity. In our analysis of the Pkinase_C domains of PKCβ and PKCθ, we found that loss of HF-motif
phosphorylation not only inactivates the kinase but results in a dominant-negative effect with respect to global
PKC signalling in the cell. Our experimental studies indicate that PKCβII HF-motif phosphorylation site mutants
are loss-of-function, supporting clinical studies and cellular studies indicating PKCβ is a tumour suppressor; thus,
failure to phosphorylate the HF-motif may contribute to disease progression by impairing PKC activity.
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Hundreds of RDF data resources, including nearly 100 in the life sciences are available within the Linked
Open Data30 (LOD) initiative. Recently, a federated query utility has been added to SPARQL, enabling aggregate
queries from distributed RDF resources that, otherwise, would be very difficult to obtain. In practice, however,
formulating such integrative SPARQL federated queries is not an easy task. To write such queries, a researcher
must (1) fully understand the organization (schema) and the contents of all of the involved RDF datasets, (2) be
familiar with the precise syntax and semantics of SPARQL and federated queries, and (3) be able to perform any
additional data analytics tasks on the retrieved results. Recently, the first problem has been partially addressed
by a system called BioFed31, which helps in selecting the data sources and automatically re-writing the query as
a federated query. However, the users must still formulate the initial SPARQL query, and many biologists are not
familiar with the SPARQL syntax and semantics. To address the second problem, we have created SPARQLing32,
a graphical SPARQL query formulation system designed for easy query formulation by people not familiar with
SPARQL. We are planning to extend SPARQLing to access remote, distributed data sources. Furthermore, we are
planning to integrate SPARQLing with statistical analysis software such as R33 for performing post-query analysis
on the returned results. Another data integration challenge arises when studying individual amino acid positions
within a protein. It is often difficult to identify the equivalent site across isoforms and orthologs because of differences in position numbering. ProKinO has addressed this issue for protein kinases by developing KinView, a tool
that, among other functions, maps protein kinase sequences to a reference protein kinase A (PKA) sequence25.
Likewise, to facilitate conservation studies of PTM and variant sites, PRO is currently developing a sub-ontology
for sites. This ontology will define classes of positions within proteins; equivalent positions in isoforms or orthologs can then be related through belonging to the same position class.
In conclusion, by integrating protein-related data from multiple sources, we explored current knowledge gaps
in the functional coverage of the human kinome, and the relationships connecting kinome cancer variants and
PTMs. We identified protein kinases in need of further curation as well as kinase functional domains where
aberrant PTM may contribute to disease; furthermore, we proposed testable hypotheses about cancer variants
altering key PTM sites and experimentally tested the hypotheses in EGFR and PKCβ. Continued development
to improve automated information retrieval across resources is necessary to enable this approach to be used on
a larger scale, and particularly to allow biologists lacking an informatics background to fully make use of these
invaluable resources.

Methods

Variant enrichment analysis. Domains enriched in disease variants were identified using a statistical test:
Variant Enrichment Analysis (VEA), which examines the frequency of mutations observed in functional domain
d across different cancer samples. In VEA, we refer to a recent study34 and assume that mutation distribution in
functional domains follows a Poisson distribution. Given this assumption, the expected number of mutations for
each domain d is defined as:
Ed =

∑EaNad,
a

(1)

where Nad is the number of amino acid a present in domain d, and the average number of mutations per amino
acid a, Ea, is given by:
Ea =

Oa
,
Na

(2)

where Oa is the number of mutations of amino acid a present in the whole human kinome across different samples, and Na is the total number of amino acid a present in the whole human kinome. For each domain d, the
parameter λ of the Poisson distribution was estimated by Ed. The significance (an upper tail p-value) of this
enrichment analysis for each domain d was generated by comparing the exact number of mutations observed in
domain d with the null distribution. Adjusted p-values of all functional domains in VEA were generated under
false discovery rate (FDR) control by Benjamini-Hochberg procedure35 (significant level: 0.005). The score of a
domain in VEA is defined as the negative log-transformation of the adjusted p-value (if the adjusted p-value is
less than 10−14, it is replaced by 10−14).
Cancer variants and protein functional domains were obtained from COSMIC (v81) and Pfam (release 30.0),
respectively. In total, there are 217,925 non-redundant protein kinase missense mutations across all cancer samples. To avoid potential bias in enrichment analyses we considered variants only from genome-wide screens
(92,222 missense mutations remained). Protein kinase mutations in COSMIC were mapped to specific positions
in the canonical UniProtKB sequence using the MAFFT alignment program36. This mapping resulted in 66,955
non-redundant missense substitutions located in 1,633 distinct functional domains in the human kinome and the
rest 25,267 mutations located in low-complexity or disorder regions.

Modification enrichment analysis. Domains enriched in post-transcriptional modifications (PTMs) were

identified using the Modification Enrichment Analysis (MEA), which examines the number of residues modified
within functional domain d. We assume the occurrence of a PTM event in each type of residue follows is an independent Bernoulli trial. Because the occurrence probabilities of all types of residue are non-identical, the number
of residues modified within a specified protein sequence interval, a functional domain, follows Poisson’s binomial distribution, which can be approximated to Poisson distribution by Poisson approximation method37,38. The
expected number of residues modified within functional domain d is defined as Ed by the same formulae (1) and
(2) with a different definition in Oa, which is defined as the number of modified residues of amino acid a present
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in the whole human kinome in MEA. The probability p of the Bernoulli trial for amino acid a is equal to Ea, while
the parameter λ of the approximated Poisson distribution for domain d is estimated by Ed. For each domain d, we
calculated the significance (an upper tail p-value) of this enrichment analysis by comparing the observed number
of residues modified within domain d with the null distribution. Adjusted p-values of all functional domains in
MEA were generated under FDR control by Benjamini-Hochberg procedure (significant level: 0.005). The score
of a domain in MEA is also defined as the negative log-transformation of the adjusted p-value (if the adjusted
p-value is less than 10−14, it is replaced by 10−14).
PTMs with their confidence scores were obtained from iPTMnet. Only manually curated PTMs with confidence scores greater than 1 were used in this study. This resulted in 16,837 PTMs mapping to 16,545 unique
positions in the human kinome.

SPARQL federated query.

Federated query is a technique for executing a distributed SPARQL query
against multiple data sets available from different SPARQL endpoints. In this study, SPARQL federated queries
were used to analyse the human kinome at both high and low levels. The high-level federated queries probed the
data volume and variety of the human kinome (Fig. 2d and Supplementary Data S1), while the low-level federated
queries integrated a variety of annotations for the protein kinases, shown in the two case studies (Table 2).
The pseudocode of the high-level federated query is shown in Supplementary Fig. S1a (all executable queries
are available at https://github.com/esbg/SPARQL). The query calculated the number of records (values) of different types of annotations (variables) from different resources (service providers) for each protein kinase. Fourteen
variables were selected from four service providers: Mutation, Reaction, Complex, Pathway, and PubMed
(human) were retrieved from ProKinO (v2.0); Homologs and Modifications were obtained from PRO (v52.0);
Expression (human), GO (human Gene Ontology), and PPI (protein-protein interaction) data were retrieved
from neXtProt (v2.9.0); GO (mouse Gene Ontology), Phenotype, Expression (mouse), and PubMed (mouse)
were retrieved from MGI dataset via Bio2RDF39 (v3.0). In addition to the number of modifications obtained from
PRO by a SPARQL query, Fig. 3a and Supplementary Data S1 also show the number of modifications extracted
directly from iPTMnet’s flat files (v4.1). The annotation score of protein kinase i, ωi, is defined as the sum of the
normalized values of all variables j:
ωi =

νij

∑ max(ν ) ,
j

j

(3)

where vij is the value of variable j for protein kinase i, and vj represents all the values of variable j for all protein
kinases. A threshold for annotation score, 1.00, is to delineate high vs. low annotation scores.
The pseudocode of the low-level federated query is shown in Supplementary Fig. S1b. It collected the values
of selected variables from the four service providers. Table 2 only show the variables described in the two case
studies. For variables with multiple values, only the values with the highest number of annotations or evidence
are shown. iPTMnet does not provide a SPARQL endpoint, so to preserve analysis integrity, annotations from
iPTMnet were manually collected and shown in Table 2.

EGFR S768 mutation analysis.

Mutagenesis. The procedure for EGFR mutational analysis is described
in our previous studies40,41. Briefly, desired point mutations (S768D, S768E, S768I) were introduced into a
pEGFP-N1-EGFR plasmid using QuikChange Site-Directed Mutagenesis Kits (Agilent Genomics, CA, USA).
Mutant plasmids were purified and confirmed via DNA sequencing.
Cell transfection and western blot analysis. Chinese Hamster Ovary (CHO) cells grown in high-glucose
Dulbecco’s modified Eagle medium (DMEM) (Cellgro, Manassas, VA, USA) with 10% fetal bovine serum
(FBS) (Bioexpress, UT, USA) to approximately 30% confluency. Lipofectamine-2000 (Thermo Fisher Scientific,
Waltham, MA, USA) was used to transfect wild-type/mutant plasmids (5 μg DNA per 30 mm plate) into CHO
cells by following the manufacturer’s protocol. After 24 hours, GFP signals of the cells were inspected under
a microscope for the transfection efficacy. CHO cells were then washed with phosphate buffered saline (PBS)
(Cellgro, Manassas, VA, USA) and serum-starved in Ham’s F-12 media with L-glutamine (Cellgro, Manassas,
VA, USA) for 18 h followed by EGF stimulation (100 ng/mL) (Sigma, St. Louis, MO, USA) for 5 min. CHO cells
population was pooled in lysis buffer (50 mM Tris HCl pH 7.4, 1 mM EDTA, 150 mM NaCl, 1% Triton X-100, and
10% glycerol) at 4 °C. 150 μl of total cell lyse were mixed with 50 μl 4X SDS PAGE sample buffer (40% glycerol,
8% SDS, 200 mM Tris-HCl PH 6.8, 0.4% bromophenol blue, and 10% 2-mercaptoethanol) and heated at 95 °C
for 7 minutes. The protein sample was resolved using 8% polyacrylamide gels and transferred to polyvinylidene
fluoride (PVDF) membrane for western blot analysis. Membrane was blocked in 4% BSA-TBST buffer (4% bovine
serum albumin, 5 mM Tris, 15 mM NaCl, 0.1% Tween 20, PH 8.0). The EGFR expression and autophosphorylation signal were probed using anti-GFP, anti-Y845-EGFR, anti-Y1197-EGFR antibodies (Cell Signaling, MA,
USA). Downstream STAT3 signalling was probed using anti-Y705-STAT3, and anti-STAT3 antibodies (Cell
Signaling, MA, USA). The membrane was visualized using Pierce ECL substrate (Thermo Scientific, MA, USA)
for 5 minutes.
Equipment and settings. The digital images were scanned using EPSON perfection 4490 photo scanner at 300
dpi resolution. All resulting images were converted to black and white using Inkscape. The reported images are
neither cropped nor enhanced by any means of post-processing.
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PKCβII S660 mutation analysis.

Plasmid constructs and reagents. The C Kinase Activity Reporter
(CKAR) was previously described28. mCherry-tagged constructs were cloned into pcDNA3 with mCherry
at the N-terminus at the BamHI and XbaI sites. All mutants were generated by QuikChange II Site-Directed
Mutagenesis (Agilent). Phorbol 12,13-dibutyrate (PDBu) and uridine-5’-triphosphate (UTP) were purchased
from Sigma-Aldrich.

Cell culture and transfection. COS-7 cells were cultured in DMEM (Corning) containing 10% fetal bovine serum
(Atlanta Biologicals) and 1% penicillin/streptomycin (GIBCO) at 37 °C in 5% CO2. Transient transfection was
carried out using the Lipofectamine 3000 Transfection Reagent (Thermo Fisher Scientific).
FRET imaging and analysis. Cells were plated onto glass coverslips in 35 mm dishes, transfected with the indicated constructs, and imaged in Hanks’ balanced salt solution supplemented with 1 mM CaCl2. CFP, YFP, and
FRET images were acquired with a 403 objective with a Zeiss Axiovert microscope (Carl Zeiss Microimaging)
using an iXon Ultra EMCCD camera (Andor Technology) controlled by MetaFluor software version 7.10.1.161
(Universal Imaging) as described previously42. For activity experiments, COS-7 cells were co-transfected with the
indicated mCherry-tagged PKC construct and CKAR. Baseline images were acquired every 15 s for 2 min before
ligand addition. Förster resonance energy transfer (FRET) ratios represent CFP/FRET mean ± SEM from at least
three independent experiments. All data were normalized to the baseline FRET ratio of each individual cell.
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